相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C
Jihane N. Benhammou et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents
Fasiha Kanwal et al.
HEPATOLOGY (2020)
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs
Frank Tacke et al.
LIVER INTERNATIONAL (2020)
Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy
Giuliana Amaddeo et al.
LIVER INTERNATIONAL (2020)
Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C
Ho Soo Chun et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals
Monica Pons et al.
JOURNAL OF HEPATOLOGY (2020)
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis
Scott A. McDonald et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
HEPATOLOGY (2020)
Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study
Gamal Shiha et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Postsustained Virological Response Management in Hepatitis C Patients
Chiara Masetti et al.
SEMINARS IN LIVER DISEASE (2020)
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort
Elizabeth C. Verna et al.
JOURNAL OF HEPATOLOGY (2020)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk
Naveed Z. Janjua et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination
Eiichi Ogawa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs
Elisabetta Degasperi et al.
HEPATOLOGY (2020)
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis
Sonia Alonso Lopez et al.
HEPATOLOGY (2020)
Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies
Georg Semmler et al.
JOURNAL OF HEPATOLOGY (2020)
Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication
Chung-Feng Huang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
Solomon Owusu Sekyere et al.
LIVER CANCER (2019)
HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response
Nourdine Hamdane et al.
GASTROENTEROLOGY (2019)
Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study
Tatsuya Ide et al.
HEPATOLOGY INTERNATIONAL (2019)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat et al.
LANCET (2019)
Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
Masahito Nakano et al.
CANCER MEDICINE (2019)
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
George N. Ioannou et al.
GASTROENTEROLOGY (2019)
Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy
Seong Kyun Na et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals
Elisabetta Degasperi et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response
Noam Peleg et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response
Victoria T. Muecke et al.
LIVER INTERNATIONAL (2019)
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
Shira Perez et al.
PLOS GENETICS (2019)
Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy
Nobuhiko Ogasawara et al.
HEPATOLOGY RESEARCH (2019)
A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens
Mohamed El Kassas et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2019)
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis
Hooman Farhang Zangneh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Elisabetta Degasperi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals
Ana Lleo et al.
DIGESTIVE AND LIVER DISEASE (2019)
Association of serum interferon-λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents
Emi Inoue-Shinomiya et al.
HEPATOLOGY RESEARCH (2019)
Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection
Takao Watanabe et al.
HEPATOLOGY RESEARCH (2019)
TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy
Etsuko Iio et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
Federico Pinero et al.
LIVER INTERNATIONAL (2019)
Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C
Angelo Simili et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2019)
Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment
Karin Kozbial et al.
LIVER INTERNATIONAL (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy
N. Saraiya et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection
Omar El-Sherif et al.
GASTROENTEROLOGY (2018)
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Pierre Nahon et al.
GASTROENTEROLOGY (2018)
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
Vincenza Calvaruso et al.
GASTROENTEROLOGY (2018)
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study
Antonietta Romano et al.
JOURNAL OF HEPATOLOGY (2018)
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting
Giovanni Perricone et al.
LIVER INTERNATIONAL (2018)
Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
Mazen Noureddin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection
Kentaro Matsuura et al.
GASTROENTEROLOGY (2017)
TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C
Miya John et al.
GASTROENTEROLOGY (2017)
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Jose Luis Calleja et al.
JOURNAL OF HEPATOLOGY (2017)
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
Adriaan J. van der Meer et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Reem Waziry et al.
JOURNAL OF HEPATOLOGY (2017)
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
Juan Manuel Pascasio et al.
JOURNAL OF HEPATOLOGY (2017)
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease
Fumihiro Ogata et al.
ONCOLOGY (2017)
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates
Norah A. Terrault et al.
TRANSPLANTATION (2017)
Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma
Huajie Cai et al.
ONCOLOGY LETTERS (2017)
Factors Associated with Improved Glycemic Control by Direct-Acting Antiviral Agent Treatment in Egyptian Type 2 Diabetes Mellitus Patients with Chronic Hepatitis C Genotype 4
Alaaeldin Abdelsalam Dawood et al.
DIABETES & METABOLISM JOURNAL (2017)
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response
Christoph Welsch et al.
PLOS ONE (2017)
Risk of Hepatocellular Carcinoma After Sustained Virological Response in Veterans With Hepatitis C Virus Infection
Hashem B. El-Serag et al.
HEPATOLOGY (2016)
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Luca Saverio Belli et al.
JOURNAL OF HEPATOLOGY (2016)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2016)
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Michelle C. M. Cheung et al.
JOURNAL OF HEPATOLOGY (2016)
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
Bryony Simmons et al.
CLINICAL INFECTIOUS DISEASES (2015)
Evaluation of Liver Disease Progression in the German Hepatitis C Virus (1b)-Contaminated Anti-D Cohort at 35 Years After Infection
Manfred Wiese et al.
HEPATOLOGY (2014)
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication
Chung-Feng Huang et al.
JOURNAL OF HEPATOLOGY (2014)
Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy
Chun-Hao Chen et al.
HEPATOLOGY INTERNATIONAL (2013)
Taste and appetite disorders of chronic hepatitis C patients
Joanna Musialik et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The interaction of metabolic factors with HCV infection: Does it matter?
Elisabetta Bugianesi et al.
JOURNAL OF HEPATOLOGY (2012)
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
Mei-Hsuan Lee et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
Hamish A. Innes et al.
HEPATOLOGY (2011)
Effectiveness and Safety of Everolimus in the Treatment of Autoimmune Hepatitis Related to Anti-Hepatitis C Virus Therapy After Liver Transplant: Three Case Reports
T. Casanovas et al.
TRANSPLANTATION PROCEEDINGS (2011)
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
Savino Bruno et al.
HEPATOLOGY (2007)
Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation
N Kontorinis et al.
LIVER TRANSPLANTATION (2006)
分享论文
